Tevogen Bio Holdings Inc.
TVGNAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| D. Boral Capital | downgrade | Buy →Hold | Mar 4, 2026 |
| D. Boral Capital | maintain | Buy | Mar 3, 2026 |
| D. Boral Capital | maintain | Buy | Nov 20, 2025 |
| D. Boral Capital | maintain | Buy | Sep 4, 2025 |
| D. Boral Capital | maintain | Buy | Aug 18, 2025 |
| D. Boral Capital | maintain | Buy | Aug 6, 2025 |
| D. Boral Capital | maintain | Buy | Aug 4, 2025 |
| D. Boral Capital | maintain | Buy | Jun 18, 2025 |
| D. Boral Capital | maintain | Buy | Jun 10, 2025 |
| D. Boral Capital | maintain | Buy | May 27, 2025 |
| D. Boral Capital | maintain | Buy | May 12, 2025 |
| D. Boral Capital | maintain | Buy | Apr 29, 2025 |
| D. Boral Capital | maintain | Buy | Apr 21, 2025 |
| D. Boral Capital | maintain | Buy | Mar 11, 2025 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-2.56| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-1.52 | $-2.53 | — | — |
| May 15, 2026 | $-1.61 | $-2.64 | — | — |
| Mar 31, 2026 | $-1.20 | $-1.50 | — | — |
| Nov 14, 2025 | $-1.50 | $-3.04 | — | — |
| Aug 14, 2025 | $-1.50 | $-2.50 | — | — |
| May 14, 2025 | $-3.21 | $-0.05 | — | — |
| Apr 2, 2025 | $-1.70 | $-1.70 | — | — |
| Nov 19, 2024 | $-1.74 | — | — | — |
News
Tevogen Bio Holdings Inc. (NASDAQ: TVGN - Get Free Report) shares dropped 1.6% during mid-day trading on Wednesday. The stock traded as low as $6.40 and last traded at $6.9990. 2,500 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 5,756 shares. The stock had previously closed at $7.11.
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”).
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”).
WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”)on September 29, 2026, confirming that the Company had regained compliance with the $50 million minimum market value of…